Pages that link to "Q78015006"

The following pages link to FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation (Q78015006):

Displaying 27 items.

• FGF-10 is expressed at low levels in the human prostate (Q28144257) (← links)
• Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis (Q28215493) (← links)
• Alternative splicing of fibroblast growth factor receptors in human prostate cancer (Q31912970) (← links)
• Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer (Q33520245) (← links)
• Cultured stromal cells: an in vitro model of prostatic mesenchymal biology (Q34057789) (← links)
• Suppressed prostate epithelial development with impaired branching morphogenesis in mice lacking stromal fibromuscular androgen receptor (Q35640720) (← links)
• Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia (Q35745901) (← links)
• Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia (Q35746575) (← links)
• Interleukin-6 is an autocrine growth factor in human prostate cancer. (Q35747214) (← links)
• Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia (Q36331201) (← links)
• Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting (Q36390245) (← links)
• Growth factors in benign prostatic hyperplasia: basic science implications (Q37258877) (← links)
• A signaling network in phenylephrine-induced benign prostatic hyperplasia (Q37281184) (← links)
• Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors (Q38210468) (← links)
• Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo (Q38363715) (← links)
• Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets (Q38915711) (← links)
• Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. (Q39825713) (← links)
• Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model (Q39914178) (← links)
• The senescence-associated secretory phenotype promotes benign prostatic hyperplasia (Q41840130) (← links)
• Basic fibroblast growth factor and keratinocyte growth factor over-expression in benign prostatic hyperplasia (Q43693825) (← links)
• [Pathophysiology and therapy of benign prostatic hyperplasia]. (Q52588865) (← links)
• Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN. (Q52723926) (← links)
• Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. (Q54410051) (← links)
• Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia (Q61798949) (← links)
• Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate (Q77359737) (← links)
• Therapeutic use of pulsed electromagnetic field therapy reduces prostate volume and lower urinary tract symptoms in benign prostatic hyperplasia (Q89851597) (← links)
• Stimulation of Prostate Cells by the Senescence Phenotype of Epithelial and Stromal Cells: Implication for Benign Prostate Hyperplasia (Q92030387) (← links)